2025 NOSCM | Updates on ROS-1, RET, BRAF, MET & NTRK

2025 NOSCM | Updates on ROS-1, RET, BRAF, MET & NTRK

0% Complete

Course Overview

Dr. Janakiram Subramanian discussed KRAS and HER2 mutations, noting the potential of new agents like zongertinib.

Course Content

Course Details

Duration
0.00 hour
Released
Jul 25, 2025
Last Review
Jul 25, 2025
Expires
Jul 25, 2026

Objectives

NA

Target Audience

Physicians
Nurses
Pharmacists
Physician Associates

Faculty & Disclosure

Faculty

Janakiram Subramanian, MD, MPH

Disclosure

<p>NA</p>

Accreditation

NA